Lamberto Andreotti new head of Bristol-Myers Squibb
pharmafile | March 4, 2010 | Appointment | Research and Development, Sales and Marketing | BMS, appointment, research and development, sales and marketing
Bristol-Myers Squibb has appointed Lamberto Andreotti its new chief executive with effect from 4 May, succeeding James Cornelius who will remain as the company’s chairman.
Andreotti said: “Jim successfully led our transformation into a next-generation biopharma leader with his strategic leadership and consistent focus on delivering our commitments. I am personally grateful for this opportunity to lead Bristol-Myers Squibb in the next phase of our biopharma journey.
Andreotti is currently responsible for the BMS’ global pharmaceutical business, holding the roles of president and chief operating officer.
He has been with the company for 12 years in senior leadership roles, both internationally and in the US. Prior to joining BMS he held senior roles at KABI Pharmacia and then at Pharmacia & Upjohn.
“While challenges lie ahead, we are confident we can overcome them as we continue to successfully execute and deliver operationally, financially and strategically to maximise our future opportunities. As we succeed, the ultimate beneficiaries are patients who we help prevail against serious diseases,” he added.
Related Content
Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …
BMS acquires Mirati Therapeutics for $4.8bn
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a …
BMS shares new research and development plans at the company’s R&D day
Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, …